Soluble Fcγ receptor III (CD16) and eicosanoid concentrations in gut lavage fluid from patients with inflammatory bowel disease: Reflection of mucosal inflammation

Gut

Volumn 38, Issue 4, 1996, Pages 564-567

  Hommes, D W ^a,c   Meenan, J ^a   De Haas, M ^b   Ten Kate, F J W ^a   Von Dem Borne, A E G Kr ^a   Tytgat, G N J ^a   Van Deventer, S J H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Eicosanoids; Fc receptor III; Gut lavage fluid; Inflammatory bowel disease

Indexed keywords

FC RECEPTOR; ICOSANOID; LEUKOTRIENE B4; PROSTAGLANDIN E2; THROMBOXANE B2;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENDOSCOPY; ENTERITIS; HISTOPATHOLOGY; HUMAN; MUCOSA INFLAMMATION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0030007163     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.4.564     Document Type: Article

References (30)

1. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365-76.
2. 4 in inflammation. Crit Rev Immunol 1990; 10: 1-12.
3. 4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86: 453-60.
4. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis and Clostridium difficile colitis. Gastroenterology 1988; 95: 11-7.
5. 4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986; 91: 837-44.
6. Phipps RP, Stein SH, Roper RL. A new view of prostaglandin E regulation of the immune response. Immunol Today 1991; 12: 349-52.
7. Hawkey CJ, Karmeli F, Rachmilewitz D. Imbalance of prostacyclin and thromboxane synthesis in Crohn's disease. Gut 1983; 24: 881-5.
8. 2 induces ulceration of the gastric mucosa. Nature 1981; 292: 472-4.
9. Percy WH, Burton MB, Fallick F, Burakoff R. A comparison in vitro of human and rabbit distal colonic muscle responses to inflammatory mediators. Gastroenterology 1990; 99: 1324-32.
10. Donowitz M. Arachidonic acid metabolites and their role in inflammatory bowel disease. Gastroenterology 1985; 88: 580-7.
11. Fleit HB, Wright SD, Unkeless JC. Human neutrophil Fcγ receptor distribution and structure. Proc Natl Acad Sci USA 1982; 79: 3275-9.
12. Perussia B, Trinchieri G. Antibody 3G8, specific for the human neutrophil Fc receptor, reacts with natural killer cells. J Immunol 1984; 132: 1410-5.
13. Clarkson SB, Kimberly RB, Valinsky JE, Witmer MD, Bussell JB, Nachman RL, Unkeless JC. Blockade of clearance of immune complexes by anti-FcR monoclonal antibody. J Exp Med 1986; 164: 474-89.
14. Clarkson SB, Ory PA. CD16: developmentally regulated IgG Fc receptors on cultured human monocytes. J Exp Med 1988; 167: 408-20.
15. Huizinga TW, Kleijer M, Tetteroo PA, Roos D, von dem Borne AEGKr. Biallelic neutrophil NA-antigen system is associated with a polymorphism on the phospho-inositol-linked Fc gamma receptor III (CD16). Blood 1990; 75: 213-20.
16. Fleit HB, Kobasiuk CB, Doly C, Furie R, Levy PC, Webster RO. A soluble form of FcγRIII is present in human serum and other body fluids and is elevated at sites of inflammation. Blood 1992; 79: 2721-8.
17. O'Mahony S, Barton JR, Crichton S, Ferguson A. Appraisal of gut lavage in the study of intestinal humoral immunity. Gut 1990; 31: 1341-4.
18. O'Mahony S, Choudari CP, Barton JR, Walker S, Ferguson A. Gut lavage fluid proteins as markers of activity of inflammatory bowel disease. Scand J Gastroenterol 1991; 26: 940-4.
19. Choudari CP, O'Mahony S, Brydon G, Mwantembe O, Ferguson A. Gut lavage protein concentrations: objective measures of disease activity in inflammatory bowel disease. Gastroenterology 1993; 104: 1064-71.
20. Brydon WG, Choudari CP, Ferguson A. Relative specificity for active inflammatory bowel disease of plasma-derived proteins in gut lavage fluid. Eur J Gastroenterol Hepatol 1993; 5: 269-73.
21. Mulder CJJ, Tytgat GNJ, Wiltink EHH, Houthoff HJ. Comparison of 5-aminosalicylic acid (3 g) and prednisolone phosphate sodium enemas (30 mg) in the treatment of distal ulcerative colitis: a prospective, randomized double blind trial. Scand J Gastroenterol 1988; 23: 1005-8.
22. Seldenrijk CA, Morson BC, Meuwissen SGM, Schipper NW, Lindeman J, Meijer CJLM. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease; diagnostic implications. Gut 1991; 32: 1514-20.
23. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as a single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978; 13: 833-7.
24. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
25. Huizinga TWJ, de Haas M, van Oers MHJ, Kleijer M, Vile H, van der Wouw PA, et al. The plasma concentration of soluble Fc-gamma RIII is related to production of neutrophils. Br J Haematol 1994; 87: 459-63.
26. Huizinga TWJ, van der Schoot CE, Jost C, Klaassen R, Kleijer M, von dem Borne AEG, et al. The PI-linked receptor FcRIII is released on stimulation of neutrophils. Nature 1988; 333: 667.
27. Huizinga TW, de Haas M, Kleijer M, Nuijens JH, Roos D, von dem Borne AEGKr. Soluble Fc gamma receptor III in human plasma originates from release by neutrophils. J Clin Invest 1990; 86: 416-23.
28. De Haas M, Kleijer M, Minchinton RM, Roos D, von dem Borne AEGKr. Soluble FcγRIIIa is present in plasma and is derived from natural killer cells. J Immunol 1994; 152: 900-7.
29. Laursen LS, Naesdal J, Bukhave K, Lauritsen K, RaskMadsen J. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 1990; 335: 683-5.
30. Zijlstra FJ, Wilson JH. 15-HETE is the main eicosanoid present in mucus of ulcerative proctocolitis. Prostaglandins Leukot Essent Fatty Acids 1991; 43: 55-9.